Eisai sets up in Brazil
pharmafile | April 8, 2011 | News story | Sales and Marketing | Brazil, Eisai
Japanese pharma company Eisai has set up its first operations in Latin America, establishing a sales subsidiary in Brazil.
Based in the country’s largest city of San Paulo, Eisai Participações Ltda (Eisai Brazil) is currently working on establishing its strategy and setting up the necessary infrastructure.
Once fully up and running it will function as a direct subsidiary of the company’s US pharmaceutical operations.
Brazil is one of the key BRIC group of emerging markets, along with Russia, India and China, and the tenth largest pharmaceutical market in the world.
In common with many of its pharma peers Eisai sees significant growth opportunities as these countries.
At its Information Meeting last month the company said it expects to see increased access to medicines and pharmaceutical products in Brazil following the recent 30% increase in healthcare spending by the country’s new government.
Dominic Tyer
Related Content
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …

Eisai and EcoNaviSta enter dementia collaboration
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating …

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …






